Finoriq research workspace
BICYCLE THERAPEUTICS PLC (BCYC) SEC Filings & Filing Highlights
Review SEC filings, SEC-derived company events, filing highlights, source excerpts, and material disclosure activity for BICYCLE THERAPEUTICS PLC (BCYC).
Company Snapshot
- Company
- BICYCLE THERAPEUTICS PLC (BCYC)
- Ticker
- BCYC
- Market Cap
- $288.7M
- Latest Price
- $4.135
- Industry
- Biotech & Pharma
BICYCLE THERAPEUTICS PLC (BCYC) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for BICYCLE THERAPEUTICS PLC (BCYC).
| Event | Form | Date |
|---|---|---|
| Ordinary ResolutionsBicycle Therapeutics plc (the “Company”) held its annual general meeting of shareholders (the “AGM”) on June 17, 2026. Each of the proposal... | 8-K5.07 | 2026-06-18 |
| Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual MeetingBicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting | 8-K8.01 | 2026-05-21 |
| Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial ResultsBicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results | 8-K2.02 | 2026-04-30 |
| Bicycle Therapeutics Provides Update on Nuzefatide Pevedotin and EphA2 Pipeline at the AACR Ann...Bicycle Therapeutics Provides Update on Nuzefatide Pevedotin and EphA2 Pipeline at the AACR Annual Meeting 2026 | 8-K8.01 | 2026-04-20 |
| On March 11, 2026, the Company’s Board of Directors appointed Jennifer Perry, Pharm.D. as Chief...On March 11, 2026, the Company’s Board of Directors appointed Jennifer Perry, Pharm.D. as Chief Operating Officer, effective as of March 17... | 8-K5.02 | 2026-03-17 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.